Literature DB >> 18783996

Accelerating risk of Fidelis lead fracture.

David Farwell1, Martin S Green, Robert Lemery, Michael H Gollob, David H Birnie.   

Abstract

BACKGROUND: Sprint Fidelis (Medtronic Inc., Minneapolis, Minnesota) is a 6.6-F implantable cardioverter-defibrillator lead. In October 2007 the manufacturer suspended distribution of Sprint Fidelis leads secondary to high early fracture rates. Reprogramming of lead impedance alerts was recommended to try to reduce inappropriate shocks.
OBJECTIVE: This study sought to assess how the hazard of Fidelis fracture varies with time, whether lead impedance alert thresholds programmed after recall have prevented inappropriate shocks, and predictors of lead fracture.
METHODS: We collected clinical and device interrogation data on all lead fractures and performed a Kaplan-Meier analysis. We performed a case control study to examine univariate and multivariate predictors of lead fracture.
RESULTS: There have been 17 lead fractures in our cohort of 480 Sprint Fidelis (model 6949) leads, median follow-up 19.8 months. The hazard of fracture increased significantly with time by a power of 2.74 (95% confidence interval: 2.57 to 2.91, P <.0001). Reprogrammed lead impedance thresholds prevented inappropriate shocks in only 1 of 6 patients. Independent predictors of lead fracture were greater left ventricular ejection fraction (P = .0011) and noncephalic venous access (P = .0224).
CONCLUSION: The risk of lead fracture increased with time by a power of 2.74. Reprogrammed lead impedance thresholds prevented inappropriate shocks in only 1 of 6 patients. Independent predictors of lead fracture were greater left ventricular ejection fraction and noncephalic access.

Entities:  

Mesh:

Year:  2008        PMID: 18783996     DOI: 10.1016/j.hrthm.2008.06.024

Source DB:  PubMed          Journal:  Heart Rhythm        ISSN: 1547-5271            Impact factor:   6.343


  7 in total

Review 1.  Strategic choices to reduce implantable cardioverter-defibrillator-related morbidity.

Authors:  Oussama Wazni; Bruce L Wilkoff
Journal:  Nat Rev Cardiol       Date:  2010-04-20       Impact factor: 32.419

2.  Characteristics of Sprint Fidelis lead failure.

Authors:  R J Beukema; A R Ramdat Misier; P P H M Delnoy; J J J Smit; A Elvan
Journal:  Neth Heart J       Date:  2010-01       Impact factor: 2.380

3.  The Sprint Fidelis lead fracture story: time to come to our senses?

Authors:  P F H M van Dessel
Journal:  Neth Heart J       Date:  2010-01       Impact factor: 2.380

Review 4.  Considerations for cardiac device lead extraction.

Authors:  Oussama Wazni; Bruce L Wilkoff
Journal:  Nat Rev Cardiol       Date:  2016-01-29       Impact factor: 32.419

5.  Natural history of the Sprint Fidelis lead: survival analysis from a large single-center study.

Authors:  Leonidas Tzogias; Diego Bellavia; Shivi Sharma; Thomas J Donohue; Mark H Schoenfeld
Journal:  J Interv Card Electrophysiol       Date:  2012-06       Impact factor: 1.900

6.  Primary prevention with ICDs, are we on the right track?

Authors:  A A M Wilde; T A Simmers
Journal:  Neth Heart J       Date:  2009-03       Impact factor: 2.380

7.  Can we predict and prevent adverse events related to high-voltage implantable cardioverter defibrillator lead failure?

Authors:  Renato Pietro Ricci; Carlo Pignalberi; Barbara Magris; Stefano Aquilani; Vito Altamura; Loredana Morichelli; Antonio Porfili; Laura Quarta; Fabio Saputo; Massimo Santini
Journal:  J Interv Card Electrophysiol       Date:  2011-09-01       Impact factor: 1.900

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.